You are here

EMA

How Pharmaceuticals Impact the Environment: EMA Revises Guideline

How Pharmaceuticals Impact the Environment: EMA Revises Guideline

RAPS.org

environmental concerns

Flag link:

FDA to Follow EMA With Move From London to Amsterdam

FDA to Follow EMA With Move From London to Amsterdam

RAPS.org

Flag link:

Sanofi teams with non-profit on a landmark new drug for sleeping sickness

Sanofi teams with non-profit on a landmark new drug for sleeping sickness

Endpoints

sleeping sickness

Flag link:

FDA, EMA delay review of Opdivo/Yervoy for first-line NSCLC

FDA, EMA delay review of Opdivo/Yervoy for first-line NSCLC

BioCentury

Bristol-Myers Squibb

non-small cell lung cancer

Flag link:

Shire's drug for rare swelling disorder wins European panel green light

Shire's drug for rare swelling disorder wins European panel green light

Reuters

Flag link:

EMA Accepts Bluebird Bio's Marketing Authorization Application for Gene Therapy for Rare Blood Disorder

EMA Accepts Bluebird Bio's Marketing Authorization Application for Gene Therapy for Rare Blood Disorder

CP Wire

transfusion-dependent anemia

Flag link:

Pfizer responds to FDA, EMA and Canada after reinspections of plant that makes injected painkillers

Pfizer responds to FDA, EMA and Canada after reinspections of plant that makes injected painkillers

Fierce Pharma

drug manufacturing

Flag link:

Roche gets some regulatory love for its breakthrough quest on a PhIII Huntington’s drug

Roche gets some regulatory love for its breakthrough quest on a PhIII Huntington’s drug

Endpoints

Huntington's disease

Flag link:

Brexit forces EMA to suspend tasks as job loss forecast jumps

Brexit forces EMA to suspend tasks as job loss forecast jumps

Fierce Biotech

Flag link:

Bluebird’s first gene therapy gets European fast track

Bluebird’s first gene therapy gets European fast track

PM Live

Flag link:

Alnylam Receives Positive CHMP Opinion for Hereditary Amyloidosis Treatment

Alnylam Receives Positive CHMP Opinion for Hereditary Amyloidosis Treatment

CP Wire

hATTR amyloidosis

Flag link:

Regulators recall valsartan after finding impurity tied to cancer risk

Regulators recall valsartan after finding impurity tied to cancer risk

Biopharma Dive

Flag link:

CHMP Issues Positive Opinion to Expand Labeling of Jardiance, Synjardy and Glyxambi to Include Positive Effects on Cardiovascular and Renal Outcomes

CHMP Issues Positive Opinion to Expand Labeling of Jardiance, Synjardy and Glyxambi to Include Positive Effects on Cardiovascular and Renal Outcomes

CP Wire

Boehringer Ingelheim

Flag link:

Kite Receives Positive Opinion from CHMP for Yescarta in Lymphoma

Kite Receives Positive Opinion from CHMP for Yescarta in Lymphoma

CP Wire

Gilead Sciences

B-cell lymphoma

Flag link:

CHMP reverses course on neratinib, handing Puma an unexpected win on European marketing vote — shares soar

CHMP reverses course on neratinib, handing Puma an unexpected win on European marketing vote — shares soar

Endpoints

Puma Biotechnology

Flag link:

Pfizer's PARP Inhibitor Talazoparib Gets FDA Priority Review and EMA Submission

Pfizer's PARP Inhibitor Talazoparib Gets FDA Priority Review and EMA Submission

CP Wire

BRCA-mutant breast cancer

metastatic breast cancer

priority review

Flag link:

Pfizer Receives Good News for Trazimera (trastuzumab) Biosimilar

Pfizer Receives Good News for Trazimera (trastuzumab) Biosimilar

CP Wire

Flag link:

Regulators flag possible birth defect link to GSK's HIV drug

Regulators flag possible birth defect link to GSK's HIV drug

Yahoo/Reuters

Flag link:

EMA Validates Bristol-Myers Squibb’s Variation Application for Opdivo Plus Yervoy Combination for Treatment of First-Line Metastatic Non-Small Cell Lung Cancer

EMA Validates Bristol-Myers Squibb’s Variation Application for Opdivo Plus Yervoy Combination for Treatment of First-Line Metastatic Non-Small Cell Lung Cancer

CP Wire

Bristol-Myers Squibb

metastatic non-small cell lung cancer

Flag link:

AbbVie Submits Marketing Application to the European Medicines Agency for Risankizumab in Plaque Psoriasis

AbbVie Submits Marketing Application to the European Medicines Agency for Risankizumab in Plaque Psoriasis

CP Wire

Flag link:

Pages